8-K
Lifeloc Technologies, Inc (LCTC)
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C.
20549
FORM 8-K
Pursuant to Section
13 or 15(d) of the Securities Exchange Act of 1934
Date of Report(Date of earliest event reported): May 12, 2022 (May11, 2022)
LIFELOC TECHNOLOGIES,
INC.
(Exact name of registrantas specified in its charter)
| Colorado | 000-54319 | 84-1053680 |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
| 12441 West 49th Ave., Unit 4 | ||
| --- | --- | |
| Wheat Ridge, CO | 80033 | |
| (Address of Principal Executive Offices) | (Zip Code) |
(303) 431-9500
(Registrant’stelephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR<br> 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Stock | LCTC | N/A |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 2.02 | Results of Operations and Financial Condition. |
|---|
On May 11, 2022, Lifeloc Technologies, Inc. (the “Company”) issued a press release announcing its operating results for the quarter ended March 31, 2022. This press release was made available on the Company’s website as of May 11, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.
The information in this Form 8-K, including the exhibit attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any Company filing under the Securities Act of 1933, as amended, unless expressly set forth by specific reference in such filing that such information is incorporated by reference therein.
| Item 9.01 | Financial Statements and Exhibits. |
|---|
(d) Exhibits.
| Exhibit No. | Description |
|---|---|
| 99.1 | Press Release, dated May 11, 2022, issued by the Company |
| 104 | Cover<br>Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
SIGNATURES
Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: May 12, 2022 | LIFELOC TECHNOLOGIES, INC. | |
|---|---|---|
| By: | /s/ Vern D. Kornelsen | |
| Chief Financial Officer and Secretary |
Exhibit 99.1
LifelocReports First Quarter 2022 Results
WHEAT RIDGE, Colo., May 11, 2022 -- Lifeloc Technologies, Inc. (OTC: LCTC), a global leader in the development and manufacturing of breath alcohol and drug testing devices, has announced financial results for the first quarter ended March 31, 2022.
FirstQuarter Financial Highlights
Lifeloc posted quarterly net revenue of $2.161 million resulting in a quarterly net loss of $(145) thousand, or $(0.06) per diluted share. These results compare to net revenue of $1.810 million and quarterly net profit of $403 thousand, or $0.16 per diluted share in the first quarter of 2021. The first quarter 2021 results include a gain of $465 thousand from the SBA Paycheck Protection Program loan forgiveness. Revenue for the quarter increased by 19% versus the first quarter last year, primarily through demand recovery from the COVID-19 global pandemic as well as new product adoption. Increasing research and development investment contributed to the loss in this quarter.
New platform LX9 and LT7 devices are producing strong sales growth. The L-series devices feature a high-resolution modern display with a highly customizable user interface. Their features and performance have driven penetration by meeting previously unaddressable market needs, such as wider temperature ranges and fast customization that incorporates local languages. We expect that most L-series sales will be incremental to FC-series devices rather than displacing FC sales. The L-series devices are meeting the requirements of the most modern registration standards, such as SAI’s (Standards Australia International) latest AS 3547:2019 standards for Breath Alcohol Detectors.
Our most important goal remains the convergence of the global need for rapid detection of drugs of abuse with Lifeloc’s capability of building easy-to-use portable testing equipment. We intend to use the SpinDx™ technology platform, sometimes referred to as "Lab on a Disk", to develop a series of devices and tests that could be used at roadside, emergency rooms and in workplace testing to get a rapid and quantitative measure for a panel of drugs of abuse. The first test we intend to offer is the SpinDx device with disks for delta-9-THC detection from an oral fluid sample collected from a test subject. Then we intend to offer a device based on our recently updated LX9 breathalyzer to collect a sample for analysis from breath, which coupled with the SpinDx device will be our marijuana breathalyzer system. We have improved the detection sensitivity for delta-9-THC as well as the test speed and robustness of the device. We are continuing to work on developing this system into a device that can be used for roadside testing, as well as other contexts requiring fast response. Additional personnel and new equipment resources have been committed to finalizing the development of the first products of the SpinDx technology platform.
“We are glad to see more sales recovery in 2022, with many customers having deferred new equipment purchases during the pandemic,” commented Dr. Wayne Willkomm, President and CEO. “However, we are not just relying on pent up demand for sales growth, but instead our strong pipeline of recent and upcoming product releases will be the big driver. The Easycal® calibration station and the premium L-series devices are finding broad acceptance and the R.A.D.A.R.® 200 devices have been released to sales. The L-series devices have grown from a small base to a significant contributor to revenue and margin. Revenue from these is expected to provide the continued funding to push the SpinDx product platform across the finish line to commercialization. Research and development expenses will remain high in this push to complete the first of many products built on the SpinDx platform, prioritizing substantial value creation over short-term profitability. We are working towards the goal of initial SpinDx sales this year.”
About Lifeloc Technologies
Lifeloc Technologies, Inc. (OTC: LCTC) is a trusted U.S. manufacturer of evidential breath alcohol testers and related training and supplies for Workplace, Law Enforcement, Corrections and International customers. Lifeloc stock trades over-the-counter under the symbol LCTC. We are a fully reporting Company with our SEC filings available on our web site, www.lifeloc.com/investor.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which involve substantial risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. All forward-looking statements expressed or implied in this press release, including statements about our strategies, expectations about new and existing products, market demand, acceptance of new and existing products, technologies and opportunities, market size and growth, and return on investments in products and market, are based on information available to us on the date of this document, and we assume no obligation to update such forward-looking statements. Investors are strongly encouraged to review the section titled “Risk Factors” in our SEC filings.
Easycal® and R.A.D.A.R.^®^ are registered trademarks of Lifeloc Technologies, Inc.
SpinDx™ is a trademark of Sandia Corporation.
Amy Evans
Lifeloc Technologies, Inc.
http://www.lifeloc.com
(303) 431-9500
LIFELOC TECHNOLOGIES, INC.
Condensed Balance Sheets ****
| ASSETS | ||||||
|---|---|---|---|---|---|---|
| March 31, 2022 (Unaudited) | December 31, 2021 | |||||
| CURRENT ASSETS: | ||||||
| Cash | $ | 2,018,828 | $ | 2,571,668 | ||
| Accounts receivable, net | 798,748 | 562,092 | ||||
| Inventories, net | 2,514,112 | 2,668,789 | ||||
| Prepaid expenses and other | 167,006 | 56,897 | ||||
| Total current assets | 5,498,694 | 5,859,446 | ||||
| PROPERTY AND EQUIPMENT, at cost: | ||||||
| Land | 317,932 | 317,932 | ||||
| Building | 1,928,795 | 1,928,795 | ||||
| Real-time Alcohol Detection And Recognition equipment and software | 569,448 | 569,448 | ||||
| Production equipment, software and space modifications | 958,785 | 958,785 | ||||
| Training courses | 432,375 | 432,375 | ||||
| Office equipment, software and space modifications | 216,618 | 216,618 | ||||
| Sales and marketing equipment and space modifications | 226,356 | 226,356 | ||||
| Research and development equipment, software and space modifications | 467,485 | 456,685 | ||||
| Less accumulated depreciation | (2,628,470 | ) | (2,518,966 | ) | ||
| Total property and equipment, net | 2,489,324 | 2,588,028 | ||||
| OTHER ASSETS: | ||||||
| Patents, net | 115,920 | 134,428 | ||||
| Deposits and other | 163,480 | 163,480 | ||||
| Deferred taxes | 248,024 | 204,449 | ||||
| Total other assets | 527,424 | 502,357 | ||||
| Total assets | $ | 8,515,442 | $ | 8,949,831 | ||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||
| CURRENT LIABILITIES: | ||||||
| Accounts payable | $ | 295,523 | $ | 445,985 | ||
| Term loan payable, current portion | 48,887 | 48,513 | ||||
| Customer deposits | 166,100 | 170,952 | ||||
| Accrued expenses | 155,299 | 298,530 | ||||
| Deferred revenue, current portion | 74,460 | 71,604 | ||||
| Reserve for warranty expense | 46,500 | 46,500 | ||||
| Total current liabilities | 786,769 | 1,082,084 | ||||
| TERM LOAN PAYABLE, net of current portion and | ||||||
| debt issuance costs | 1,255,727 | 1,267,551 | ||||
| DEFERRED REVENUE, net of current portion | 6,486 | 6,430 | ||||
| Total liabilities | 2,048,982 | 2,356,065 | ||||
| COMMITMENTS AND CONTINGENCIES | ||||||
| STOCKHOLDERS' EQUITY: | ||||||
| Common stock, no par value; 50,000,000 shares | ||||||
| authorized, 2,454,116 shares outstanding | 4,668,014 | 4,650,812 | ||||
| Retained earnings | 1,798,446 | 1,942,954 | ||||
| Total stockholders' equity | 6,466,460 | 6,593,766 | ||||
| Total liabilities and stockholders' equity | $ | 8,515,442 | $ | 8,949,831 |
**** LIFELOC TECHNOLOGIES, INC. Condensed Statements of Income (Unaudited)
| Three Months Ended March 31, | ||||||
|---|---|---|---|---|---|---|
| REVENUES: | 2022 | 2021 | ||||
| Product sales | $ | 2,111,757 | $ | 1,775,447 | ||
| Royalties | 26,640 | 12,564 | ||||
| Rental income | 22,239 | 21,532 | ||||
| Total | 2,160,636 | 1,809,543 | ||||
| COST OF SALES | 1,318,747 | 985,666 | ||||
| GROSS PROFIT | 841,889 | 823,877 | ||||
| OPERATING EXPENSES: | ||||||
| Research and development | 390,024 | 307,212 | ||||
| Sales and marketing | 276,637 | 230,478 | ||||
| General and administrative | 352,833 | 350,120 | ||||
| Total | 1,019,494 | 887,810 | ||||
| OPERATING INCOME (LOSS) | (177,605 | ) | (63,933 | ) | ||
| OTHER INCOME (EXPENSE): | ||||||
| Forgiveness of Paycheck Protection loan | — | 465,097 | ||||
| Interest income | 432 | 499 | ||||
| Interest expense | (10,910 | ) | (13,517 | ) | ||
| Total | (10,478 | ) | 452,079 | |||
| NET INCOME (LOSS) BEFORE PROVISION FOR TAXES | (188,083 | ) | 388,146 | |||
| BENEFIT FROM (PROVISION FOR) FEDERAL AND STATE INCOME TAXES | 43,575 | 15,325 | ||||
| NET INCOME (LOSS) | $ | (144,508 | ) | $ | 403,471 | |
| NET INCOME (LOSS) PER SHARE, BASIC | $ | (0.06 | ) | $ | 0.16 | |
| NET INCOME (LOSS) PER SHARE, DILUTED | $ | (0.06 | ) | $ | 0.16 | |
| WEIGHTED AVERAGE SHARES, BASIC | 2,454,116 | 2,454,116 | ||||
| WEIGHTED AVERAGE SHARES, DILUTED | 2,454,116 | 2,454,116 |
**** Lifeloc Technologies, Inc. Condensed Statements of Stockholders' Equity (Unaudited)
| Three Months Ended March 31, | |||||
|---|---|---|---|---|---|
| 2022 | 2021 | ||||
| Total stockholders' equity, beginning balances | $ | 6,593,766 | $ | 5,900,642 | |
| Common stock (no shares issued during periods): | |||||
| Beginning balances | 4,650,812 | 4,633,655 | |||
| Stock based compensation expense related | |||||
| to stock options | 17,202 | 17,157 | |||
| Ending balances | 4,668,014 | 4,650,812 | |||
| Retained earnings: | |||||
| Beginning balances | 1,942,954 | 1,266,987 | |||
| Net income (loss) | (144,508 | ) | 403,471 | ||
| Ending balances | 1,798,446 | 1,670,458 | |||
| Beginning balances | 6,593,766 | 5,900,642 | |||
| Net income (loss) | (144,508 ) | 403,471 | |||
| Total stockholders' equity, ending balances | $ | 6,466,460 | $ | 6,321,270 |
**** LIFELOC TECHNOLOGIES, INC. Condensed Statements of Cash Flows (Unaudited)
| Three Months Ended March 31, | ||||||
|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES: | 2022 | 2021 | ||||
| Net income (loss) | $ | (144,508 | ) | $ | 403,471 | |
| Adjustments to reconcile net income to net cash | ||||||
| provided from (used in) operating activities- | ||||||
| Forgiveness of Paycheck Protection loan (round 1) | — | (465,097 | ) | |||
| Depreciation and amortization | 129,088 | 66,828 | ||||
| Provision for inventory obsolescence, net change | 34,789 | — | ||||
| Deferred taxes, net change | (43,575 | ) | (1,441 | ) | ||
| Stock based compensation expense related to | ||||||
| stock options | 17,202 | 17,157 | ||||
| Changes in operating assets and liabilities- | ||||||
| Accounts receivable | (236,656 | ) | (169,622 | ) | ||
| Inventories | 119,888 | (82,022 | ) | |||
| Income taxes receivable | — | (13,884 | ) | |||
| Prepaid expenses and other | (110,109 | ) | (20,606 | ) | ||
| Accounts payable | (150,462 | ) | 21,968 | |||
| Customer deposits | (4,852 | ) | 6,170 | |||
| Accrued expenses | (143,231 | ) | (102,547 | ) | ||
| Deferred revenue | 2,912 | 2,249 | ||||
| Net cash provided from (used in) | ||||||
| operating activities | (529,514 | ) | (337,376 | ) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||
| Purchases of property and equipment | (10,800 | ) | — | |||
| Net cash (used in) investing activities | (10,800 | ) | — | |||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||
| Proceeds from Paycheck Protection loan (round 2) | — | 471,347 | ||||
| Principal payments made on term loan | (12,526 | ) | (12,006 | ) | ||
| Net cash (used in) financing | ||||||
| activities | (12,526 | ) | 459,341 | |||
| NET INCREASE (DECREASE) IN CASH | (552,840 | ) | 121,965 | |||
| CASH, BEGINNING OF PERIOD | 2,571,668 | 2,195,070 | ||||
| CASH, END OF PERIOD | $ | 2,018,828 | $ | 2,317,035 | ||
| SUPPLEMENTAL INFORMATION: | ||||||
| Cash paid for interest | $ | 9,834 | $ | 13,246 |